MA52954A - Procédé pour la fabrication d'aminoéthers de diaryle et sels de chlorhydrate d'aminoéthers de diaryle - Google Patents

Procédé pour la fabrication d'aminoéthers de diaryle et sels de chlorhydrate d'aminoéthers de diaryle

Info

Publication number
MA52954A
MA52954A MA052954A MA52954A MA52954A MA 52954 A MA52954 A MA 52954A MA 052954 A MA052954 A MA 052954A MA 52954 A MA52954 A MA 52954A MA 52954 A MA52954 A MA 52954A
Authority
MA
Morocco
Prior art keywords
aminoethers
diaryl
manufacture
hydrochloride salts
hydrochloride
Prior art date
Application number
MA052954A
Other languages
English (en)
Inventor
Erhard Bappert
Michael Bauer
Uwe Hahn
Original Assignee
Cellestia Biotech Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellestia Biotech Ag filed Critical Cellestia Biotech Ag
Publication of MA52954A publication Critical patent/MA52954A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/73Unsubstituted amino or imino radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
MA052954A 2018-06-21 2019-06-20 Procédé pour la fabrication d'aminoéthers de diaryle et sels de chlorhydrate d'aminoéthers de diaryle MA52954A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18179034 2018-06-21

Publications (1)

Publication Number Publication Date
MA52954A true MA52954A (fr) 2021-04-28

Family

ID=62873133

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052954A MA52954A (fr) 2018-06-21 2019-06-20 Procédé pour la fabrication d'aminoéthers de diaryle et sels de chlorhydrate d'aminoéthers de diaryle

Country Status (17)

Country Link
US (2) US11472771B2 (fr)
EP (1) EP3810574A1 (fr)
JP (2) JP2021528444A (fr)
CN (2) CN119019324A (fr)
AU (1) AU2019289917B2 (fr)
BR (2) BR122023023452A2 (fr)
CA (1) CA3102129A1 (fr)
EA (1) EA202190024A1 (fr)
IL (1) IL279476B2 (fr)
MA (1) MA52954A (fr)
MX (1) MX2020014129A (fr)
PH (1) PH12020552038A1 (fr)
SA (1) SA520420837B1 (fr)
SG (1) SG11202011932SA (fr)
TW (1) TWI853819B (fr)
UA (1) UA128888C2 (fr)
WO (1) WO2019243523A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA52954A (fr) * 2018-06-21 2021-04-28 Cellestia Biotech Ag Procédé pour la fabrication d'aminoéthers de diaryle et sels de chlorhydrate d'aminoéthers de diaryle
WO2022058418A1 (fr) * 2020-09-16 2022-03-24 Cellestia Biotech Ag Nouvelle utilisation d'inhibiteurs de la voie de signalisation notch

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8430252D0 (en) 1984-11-30 1985-01-09 Beecham Group Plc Compounds
US4816373A (en) 1986-01-31 1989-03-28 Mitsubishi Paper Mills, Ltd. Method of producing images
AU4633893A (en) 1992-06-17 1994-01-04 University Of Massachusetts Medical Center Liposomal formulations for administering to cancer patients
GB9312891D0 (en) 1993-06-22 1993-08-04 Boots Co Plc Therapeutic agents
US5935924A (en) 1994-04-15 1999-08-10 Genentech, Inc. Treatment of congestive heart failure
EP0889033B1 (fr) 1995-09-29 2003-01-08 Shionogi & Co., Ltd. Derives heterocycliques de benzyle substitue en alpha, intermediaires servant a leur fabrication, et pesticides dont ils forment le principe actif
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
TR199902301T2 (xx) 1997-03-19 1999-12-21 Basf Aktiengesellschaft Pirilo $2,3D]pirimidinler ve onlar�n kullan�m�.
US6692919B1 (en) 1997-07-23 2004-02-17 Yale University Activated forms of notch and methods based thereon
EP1049664B1 (fr) * 1997-12-22 2005-03-16 Bayer Pharmaceuticals Corporation Inhibition de raf kinase au moyen de diphenylurees substituees symetriques et asymetriques
US20080269265A1 (en) * 1998-12-22 2008-10-30 Scott Miller Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas
EP1140840B1 (fr) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. Diphenylurees a substituants -g(v)-carboxyaryles, inhibitrices de kinase raf
KR100642955B1 (ko) 1999-04-23 2006-11-10 알자 코포레이션 방출성 결합 및 그를 함유하는 조성물
GB9910577D0 (en) * 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
JP2001089412A (ja) 1999-09-22 2001-04-03 Otsuka Pharmaceut Co Ltd ベンゼン誘導体またはその医薬的に許容される塩
WO2002046161A1 (fr) * 2000-12-05 2002-06-13 Kyorin Pharmaceutical Co., Ltd. Derives de l'acide carboxylique substitues
DE60221866T2 (de) 2001-10-19 2008-05-29 Ortho-Mcneil Pharmaceutical, Inc. 2-PHENYL BENZIMIDAZOLE UND IMIDAZO-i4,5ö-PYRIDINE ALS CDS1/CHK2-INHIBITOREN UND ADJUVANTIEN IN DER CHEMOTHERAPIE ODER STRAHLUNGSTHERAPIE ZUR BEHANDLUNG VON KREBS
EP1461313B1 (fr) 2001-12-14 2009-08-05 Exelixis, Inc. Inhibiteurs de l'adam-10 humaine
AU2003255735A1 (en) 2002-08-03 2004-02-23 Lorantis Limited Conjugate of notch signalling pathway modulators and their use in medical treatment
US20050214250A1 (en) 2003-11-06 2005-09-29 Harris J M Method of preparing carboxylic acid functionalized polymers
AU2005272619A1 (en) 2004-08-13 2006-02-23 Praecis Pharmaceuticals, Inc. Methods and compositions for modulating sphingosine-1-phosphate (SIP) receptor activity
CN101094829B (zh) * 2004-12-07 2012-02-08 富山化学工业株式会社 新的氨茴酸衍生物或其盐
WO2006118749A1 (fr) 2005-05-04 2006-11-09 Janssen Pharmaceutica, N.V. Inhibiteurs de la thia-tetraazaacenaphtylene kinase
GB0518232D0 (en) 2005-09-07 2005-10-19 Merck Sharp & Dohme New methods
EP1894915A1 (fr) * 2006-09-04 2008-03-05 Bayer Schering Pharma Aktiengesellschaft Dérivés de phényloxyaniline
CL2007003590A1 (es) 2006-12-12 2008-02-29 Wyeth Corp Compuestos derivados de aril sulfamida; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en prevencion y tratamiento de sintomas vasomotrices, disfuncion sexual, transtornos gastrointestinales, transt
AR068072A1 (es) 2007-04-19 2009-11-04 Novartis Ag Derivados de bencimidazoles, composiciones farmaceuticas y usos
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
GB0722055D0 (en) 2007-11-09 2007-12-19 Argenta Discovery Ltd Compounds
JP2011523655A (ja) 2008-06-03 2011-08-18 フレセニウス メディカル ケア ドイッチュランド ゲーエムベーハー ガンマセクレターゼモジュレータを含む医薬組成物
WO2010033655A1 (fr) 2008-09-19 2010-03-25 Complegen, Inc. Composés et méthodes d’inhibition de la pkc thêta
US20100292193A1 (en) 2009-04-10 2010-11-18 The Regents Of The University Of California Radioprotective drugs
RU2013138835A (ru) * 2011-02-09 2015-03-20 Ф. Хоффманн-Ля Рош Аг Гетероциклические соединения в качестве ингибиторов pi3 киназы
JPWO2013035827A1 (ja) 2011-09-09 2015-03-23 塩野義製薬株式会社 新規オレフィン誘導体
EP2606884A1 (fr) 2011-12-21 2013-06-26 Ecole Polytechnique Fédérale de Lausanne (EPFL) Inhibiteurs de la voie de signalisation notch et leur utilisation dans le traitement des cancers
CN103242237A (zh) * 2013-05-10 2013-08-14 常州亚邦齐晖医药化工有限公司 一种驱虫药芬苯达唑的制备新方法
MA52954A (fr) * 2018-06-21 2021-04-28 Cellestia Biotech Ag Procédé pour la fabrication d'aminoéthers de diaryle et sels de chlorhydrate d'aminoéthers de diaryle
JP2022528705A (ja) * 2019-04-10 2022-06-15 セレスティア バイオテック アーゲー オンコウイルス誘発性がんの治療のための化合物及びその使用方法

Also Published As

Publication number Publication date
BR112020026148A2 (pt) 2021-03-16
SG11202011932SA (en) 2021-01-28
US20240254084A9 (en) 2024-08-01
CA3102129A1 (fr) 2019-12-26
IL279476B2 (en) 2024-04-01
EP3810574A1 (fr) 2021-04-28
CN112351969A (zh) 2021-02-09
US20220388961A1 (en) 2022-12-08
IL279476A (en) 2021-01-31
AU2019289917A1 (en) 2021-01-07
US12030855B2 (en) 2024-07-09
JP2021528444A (ja) 2021-10-21
JP2024099551A (ja) 2024-07-25
CN119019324A (zh) 2024-11-26
TW202010737A (zh) 2020-03-16
KR20210034587A (ko) 2021-03-30
BR122023023452A2 (pt) 2024-02-20
AU2019289917B2 (en) 2025-01-09
IL279476B1 (en) 2023-12-01
PH12020552038A1 (en) 2021-08-02
TWI853819B (zh) 2024-09-01
UA128888C2 (uk) 2024-11-20
US11472771B2 (en) 2022-10-18
SA520420837B1 (ar) 2023-12-05
EA202190024A1 (ru) 2021-05-19
US20210323921A1 (en) 2021-10-21
WO2019243523A1 (fr) 2019-12-26
MX2020014129A (es) 2021-06-18

Similar Documents

Publication Publication Date Title
EP3794260A4 (fr) Vanne en alliage à mémoire de forme et procédé pour sa fabrication
EP3811793A4 (fr) Article pour générer un aérosol, et procédé de fabrication d'un article pour générer un aérosol
EP3686616A4 (fr) Nouveau procédé d'étalonnage de paramètre s sur puce
EP3294165A4 (fr) Procédés pour l'implantation d'une vis à os
EP3852631A4 (fr) Procédé d'imagerie
EP3647316A4 (fr) Procédé de production d'édulcorant à base d'allulose
EP3631538A4 (fr) Procédé de fabrication d'une plaque maîtresse et plaque maîtresse
EP3320998A4 (fr) Procédé pour la fabrication d'unité de palier à roulement
EP3815807A4 (fr) Procédé de fabrication d'un article moulé à la presse
EP3951813A4 (fr) Transformateur et procédé d'usinage de transformateur
EP3768487A4 (fr) Procédé de micromoulages d'articles
EP3674376A4 (fr) Composition d'électrodéposition cationique et procédé d'électrodéposition
EP4040292A4 (fr) Procédé d'instanciation de ns et nfvo
EP3349592A4 (fr) Formulation d'os à mâcher pour animal et son procédé de fabrication
EP3331516A4 (fr) Solution d'injection hyperbare de chlorhydrate de ropivacaïne et procédé pour la préparation de celle-ci
EP4221424A4 (fr) Procédé d'accès aléatoire
EP3488876A4 (fr) Nouvelle formule pour synthétiser un matériau de remplacement osseux, procédé pour sa fabrication et procédé d'application correspondant
EP3702057A4 (fr) Procédé de production d'une plaque de titane laminée à chaud
EP4021920A4 (fr) Procédé amélioré pour la préparation de chlorhydrate d'ételcalcétide
IT201900021393A1 (it) Macchina confezionatrice e metodo di confezionamento per la produzione di cartucce monouso
EP4289625A4 (fr) Procédé de formation d'image
EP4079755A4 (fr) Procédé de production d'organoïde
EP3783239A4 (fr) Pièce alvéolée et procédé d'alvéolage
EP4088932A4 (fr) Procédé d'enregistrement d'image
EP3984530A4 (fr) Capsule de type à désintégration retardée et procédé pour la produire